BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
The option exercises add cash to BioStem while issuing 500,000 common shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioStem Technologies (BSEM) received approximately $1 million in cash as its CEO and COO exercised stock options to purchase common shares. Chair and CEO Jason Matuszewski and COO Andrew Van Vurst each purchased 250,000 shares at $2.00 per share, exercising a portion of their outstanding options. Together, the purchases totaled 500,000 shares.
Management expects the capital to support the company's expanded hospital commercial push. Matuszewski said it would support broader sales coverage, expanded hospital formulary coverage—the products available for hospital use—and inventory for new accounts. Van Vurst expects the additional capital to help support inventory and infrastructure needed to serve new hospital accounts. These are intended uses of the funding, rather than completed expansions.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointExecutive option exercises provided approximately $1 million in cash to BioStem. 2.2% of market cap
- Minor point. Forward-looking: it has not happened yet and may not happen.Management expects funding to support broader sales and hospital formulary coverage.
- Minor point. Forward-looking: it has not happened yet and may not happen.Management expects funding to support inventory and infrastructure for new hospital accounts.
Negative
- Moderate pointOption exercises issued 500,000 common shares at $2.00 per share, diluting existing holders.
Key Figures
- Aggregate purchase price
- approximately $1 million
- Cash paid for option exercises
- Shares purchased per executive
- 250,000 shares
- Each of the two executives
- Total shares purchased
- 500,000 shares
- Combined option exercises
- Exercise price
- $2.00 per share
- BioStem common stock options
Key Terms
allograft medical
exercise price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Leadership investment supports expanded hospital commercial push
POMPANO BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced its Chair and Chief Executive Officer, Jason Matuszewski, and Chief Operating Officer, Andrew Van Vurst, each exercised a portion of their outstanding options to purchase 250,000 shares of BioStem common stock at an exercise price of
“This is an exciting and important time for the Company,” said Mr. Matuszewski. “Hospitals are increasingly seeking wound care and surgical solutions that are clinically supported, reliably supplied, and economically sensible and we believe we have built one of the broadest perinatal allograft portfolios in the industry to meet exactly that need. Exercising these options reflects my continued confidence in the Company, our team and the potential for our technology. I believe this capital will support broader sales coverage, expanded hospital formulary coverage, and the inventory needed to support new accounts. I am proud to reiterate my support and remain highly committed to creating long-term value for fellow shareholders.”
"Our role on the operations side is to help ensure that growth does not outpace our ability to deliver, and we've built BioStem with that objective in mind," said Mr. Van Vurst. "I see the progress every day, in our production, quality processes, and supply planning. We believe the additional capital will help support the inventory and infrastructure needed to serve new hospital accounts, and we remain focused on consistent execution for the customers and patients who rely on our products.”
Forward-Looking Statements:
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements in this press release include, without limitation, statements regarding the application of new capital received by the Company, the Company’s ability to meet market needs and the Company’s growth prospects.
Forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties which could cause actual results or outcomes to differ materially from the expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; the Company’s ability to obtain financing on terms acceptable to it, or at all; the impact of any changes in applicable laws or regulations; the Company’s accounts receivable collection risk and concentration; the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and the possibility that the Company may be adversely affected by other general economic, business, and/or competitive factors. There may be additional risks which the Company is presently unaware of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company undertakes no duty to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
About BioStem Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.
BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.
Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: pr@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342
Investor Relations:
Philip Trip Taylor, Gilmartin Group
ir@biostemtech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did BioStem's CEO and COO invest through stock option exercises?
Jason Matuszewski and Andrew Van Vurst each purchased 250,000 BioStem common shares at $2.00 per share. Their exercises totaled 500,000 shares and an aggregate purchase price of approximately $1 million.
What does BioStem expect the executive option exercise proceeds to support?
Management expects the capital to support expanded hospital commercial activity, including broader sales coverage and hospital formulary coverage. It also expects the funding to support inventory and infrastructure needed for new hospital accounts.